NEURIZON THERAPEUTICS LIMITED - News & Media

13.6%

12.5¢

Market Cap $61.53M

Healthcare Biotechnology

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company... Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications.More

Corporate Spotlight

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.
View the full Corporate Spotlight

NUZ ANNOUNCES STRONG RESULTS IN LATEST STUDY

Articles & Videos

Neurizon Therapeutics announces strong safety results in latest study

Drug candidate NUZ-001 has shown strong safety characteristics in its latest human 3D brain model study, Neurizon Therapeutics (ASX:NUZ) has confirmed this week.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify,...

14 Apr 2025 14:30 (AEST)

Neurizon finds positive results for lead drug in 3D brain model study

Neurizon Therapeutics Ltd has completed a study together with Tessara Therapeutics on the impact of NUZ-001 on a 3D model of the brain

01 Apr 2025 11:53 (AEDT)

'Maximising the potential': Neurizon prepares for HEALEY study of ALS

Neurizon Therapeutics Ltd has provided an update to its preparations for the HEALEY Platform Trial to assess products for ALS treatment

24 Mar 2025 12:05 (AEDT)

Neurizon snags US patent for NUZ-001 after winning FDA orphan status in 2024

Neurizon (ASX:NUZ) has officially snagged a U.S. patent for its neurodegenerative disease and cancer drug candidate NUZ-001, designated orphan status by the FDA last year. The microcap stock jumped +12% to 14cps in early trades, per Cboe live pricing data. The State-side move ultimately firms up ...

05 Feb 2025 10:45 (AEDT)

Neurizon's fast-track application for flagship drug in Europe received 'positively'

Neurizon's (ASX:NUZ) hopes have been lifted with a view towards winning fast-track status from a European health regulator.

11 Nov 2024 10:54 (AEDT)

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 12.5¢		Change 0.015(13.6%)		Mkt cap ! $61.53M

Open	High	Low	Value	Volume
12.0¢	13.0¢	12.0¢	$45.40K	368.6K

Buyers (Bids)

No.	Vol.	Price($)
1	457783	12.5¢

Sellers (Offers)

Price($)	Vol.	No.
13.0¢	266325	5

View Market Depth

No.	Vol.	Price($)
1	457783	0.125
2	145584	0.120
1	20000	0.115
3	51250	0.110
7	69842	0.105

Price($)	Vol.	No.
0.130	266325	5
0.135	350000	2
0.140	201859	2
0.145	490000	2
0.150	59760	2

Last trade - 16.10pm 23/04/2025 (20 minute delay)

NUZ (ASX) Chart